Serge Beaulieu, MD, PhD, FRCPC

Department of Psychiatry, McGill University, Montreal, Quebec, Canada; Douglas Mental Health University Institute, McGill University, Verdun, Quebec, Canada; Bipolar Disorders Clinic, Douglas Mental Health University Institute, McGill University, Verdun, Quebec, Canada

  • 3Articles
  • 18.7KReads
  • 2001–2025Active
  • 46Collaborators
  • 122Citations

About

Serge Beaulieu, MD, PhD, FRCPC, is affiliated with the Department of Psychiatry at McGill University and the Douglas Mental Health University Institute in Quebec, Canada. His publications focus on bipolar disorder, major depressive disorder, and weight-related metabolic effects in psychiatric treatment. He has contributed to research on personalized depression treatment using artificial intelligence, psychoeducation and cognitive-behavioral therapy in bipolar disorder, and metabolic changes associated with olanzapine therapy. His work has been published from 2001 to 2025 in Psychiatrist.com.

Publications

JCP
Artificial Intelligence in Depression – Medication Enhancement (AID-ME): A Cluster Randomized Trial of a Clinical Decision Support System for Personalized Depression Treatment Selection and Management
Original Research

Artificial Intelligence in Depression – Medication Enhancement (AID-ME): A Cluster Randomized Trial of a Clinical Decision Support System for Personalized Depression Treatment Selection and Management

August 27, 2025

This study provides preliminary evidence that longitudinal use of an AI-enabled clinical decision support system can improve outcomes in MDD.
, , , et al
JCP
Article

A Randomized Controlled Trial of Psychoeducation or Cognitive-Behavioral Therapy in Bipolar Disorder: A Canadian Network for Mood and Anxiety Treatments (CANMAT) Study

June 15, 2012

, , , et al
JCP
Letter to the Editor

Body Weight Gain, Insulin, and Leptin in Olanzapine-Treated Patients

November 1, 2001

,

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe